198 related articles for article (PubMed ID: 36289175)
1. CSF IL-8 Associated with Response to Gene Therapy in a Case Series of Spinal Muscular Atrophy.
Verma S; Perry K; Razdan R; Howell JC; Dawson AL; Hu WT
Neurotherapeutics; 2023 Jan; 20(1):245-253. PubMed ID: 36289175
[TBL] [Abstract][Full Text] [Related]
2. NFL is a marker of treatment response in children with SMA treated with nusinersen.
Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
Seo G; Kim S; Byun JC; Kwon S; Lee YJ
Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
[TBL] [Abstract][Full Text] [Related]
8. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen.
Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N
CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
[TBL] [Abstract][Full Text] [Related]
11. Changes in pNFH Levels in Cerebrospinal Fluid and Motor Evolution after the Loading Dose with Nusinersen in Different Types of Spinal Muscular Atrophy.
Badina M; Bejan GC; Sporea C; Padure L; Mirea A; Leanca MC; Axente M; Grigoras FP; Bejan M; Shelby ES; Neagu E; Ion DA
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512056
[No Abstract] [Full Text] [Related]
12. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months.
De Wel B; De Schaepdryver M; Poesen K; Claeys KG
Ann Clin Transl Neurol; 2022 Aug; 9(8):1241-1251. PubMed ID: 35833245
[TBL] [Abstract][Full Text] [Related]
13. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
Dutta D; Chandra G; Mohanakumar KP
J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.
Schorling DC; Kölbel H; Hentschel A; Pechmann A; Meyer N; Wirth B; Rombo R; ; Sickmann A; Kirschner J; Schara-Schmidt U; Lochmüller H; Roos A
Eur J Neurol; 2022 Jul; 29(7):2084-2096. PubMed ID: 35318785
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia.
Brkušanin M; Kosać A; Branković-Srećković V; Jovanović K; Perić S; Karanović J; Matijašević Joković S; Garai N; Pešović J; Nikolić D; Stević Z; Brajušković G; Milić-Rašić V; Savić-Pavićević D
Front Neurol; 2024; 15():1394001. PubMed ID: 38756215
[TBL] [Abstract][Full Text] [Related]
18. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.
Garofalo M; Bonanno S; Marcuzzo S; Pandini C; Scarian E; Dragoni F; Di Gerlando R; Bordoni M; Parravicini S; Gellera C; Masson R; Dosi C; Zanin R; Pansarasa O; Cereda C; Berardinelli A; Gagliardi S
Biol Direct; 2023 Sep; 18(1):57. PubMed ID: 37705059
[TBL] [Abstract][Full Text] [Related]
19. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
